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Summary: A laser immunonephelometric procedure for the determination of apolipoprotein E in human
serum and lipoprotein fractions was developed. Coefficients of Variation were 2.3% within-run, 4.7% be-
tween-run. The distribution of apolipoprotein E iri various lipoprotein fractions revealed a higher proportion
of apolipoprotein E in VLDL in hypertriglyceridaemic subjects (especially marked in Type III patients) than
in normal subjects. Laser immunonephelometry appears suitable for the routine measurement of apolipo-
protein E.
Immunonephelometrische Messung von Apolipoprotein E in menschlichem Serum
Zusammenfassung: Eine laserimmunonephelornetrische Methode zur Bestimmung von Apolipoprotein E in
menschlichem Serum und Lipoproteinfraktionen wurde entwickelt. Die Variationskoeffizienten waren 2,3%
(Intraassay) und 4,7% (Interassay). Die Verteilung des an Lipoproteinen gebundenen Apolipoprotein E
ergab einen höheren Anteil in den VLDL von Patienten mit einer Hypertriglyceridämie, besonders ausge-
prägt bei der Typ III Hyperlipoproteinämie, als in den VLDL normaler Personen. Die Laserimmuno-
nephelometrie erscheint geeignet für die Routinemessung von Apolipoprotein E.
Introduction
Apolipoprotein E has been reported to be an impor-
tant constituent of normal human lipoproteins (l, 2).
Its key role in the metabolism of chylomicron rern^
nants and lipoproteins induced by cholesterol feed-
ing was established in several species inchiding hu-
mans. This apolipoprotein has been found to bind to
apolipoprotein B receptors of extrahepätic cells and
to hepatic receptors, thereby regulating the choles-
terol uptake of the cells (3—6). TKe measurement of
apolipoprotein E appears to be useful for judging the
atherosclerotic risk mpre specifically (7, 8).
The concentration of apolipoprotein E in human se-
rum and lipoprotein fractions has been determined
by electroimmunoassay (9), by radial immunodiffu-
sion (10), and by radioimmunoassay (8,11—13). For
serial measurements in epidemiological studies and
general clinical use these methods are limited in ca-
pacity and time consuming. Imumuiionephelometry is
a suitable alternative for the determination of serum
proteins because of its relative simplicity, speed, and
ease of automation (14). This report describes the
development of a sensitive and specific immunoassay
for apolipoprotein E using a laser nephelometer.
The levels of apolipoprotein E in serum and lipopro-
tein fractions were determined in normal and hyper-
lipoproteinaemic subjects.
Materials and Methods
General procedures
Serum samples from normal volunteers and hyperlipoproteinae-
mic patients (aged from 23 to 62 years), taking no medications
and having fasted overnight, were analysed. Very low-density li-
poproteins (VLDL, d < l .006 kg/l) were separated from other
lipoproteins by preparalive ultracentrifugation with a Beckman
rotor 40.3 (15). Low-density and high-density lipoproteins were
separated by sodium phosphotungstate precipitation in the
d > 1.006 kg/l fraction (16). Cholesterol and triglyccrides in se-
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rum and Hpoprotcins were measurcd immcdiately by cnzymatic
mcthods (Boehringer kits, Mannheim, FRG). Beforc assay of
apolipoprotein E, serum, VLDL, and the d > 1.006 kg/l fraction
were storcd at -18°C for up to 2 months. The hyperlipoprotei-
naemic patients were classified according to the WHO criteria
(17). Diagnosis of Type III hyperlipoproteinaemia was confirmed
by analytical isoelectric focusing (18). All data are mean values
± SD. Correlations were made by linear regression analysis.
Isolation of apolipoprotein E and production of antiserum
Apolipoprotein E was isolated from tetramethylurea-delipidated
VLDL of hypertriglyceridaemic subjects by Sephacryl S 200 gel
filtration and chromatofocusing äs described (19). The homoge-
neity of apolipoprotein used äs antigen and Standard was assayed
by polyacrylamide gel electrophoresis in sodium dodecyl sulphate
(20), and by isoelectric focusing. The Lowry technique (21) was
used for protein determination with bovine serum albumin.as pro-
tein Standard. Antisera to apolipoprotein E were produced by in-
jecting rabbits subcutaneously on 3 occasions 14 days apart and
bleeding them 7 days after the last injection. The total amount of
antigen given per inoculation was 0.3 mg apolipoprotein E dis-
solved in 0.05 ml 0.01 mol/1 NHUHCOs buffer, pH 8.6, and emul-
sified in an equal volume of complete Freundes adjuvant'(Difco,
Detroit, U.S.A.). The purity and specifity of the antiserum was
checked by double immunodiffusion and immunoelectrophoresis
using whole serum än'd purified apolipoprotein fractions.
The antiserum titer was determined by immunonephelometric ti-
tration. Serial dilutions of isolated apolipoprotein E dissolved in
0.01 mol/1 sodium phosphate buffer, pH 7.4, were incubated with
a 10 fold dilution of antiserum. Maximal light scattering was
achieved with 0.91 g/l apolipoprotein E.
Light scattering measurements
We measured the light scattering produced by the antigen-anti-
body complex with a laser nephelometer (Behringwerke, Mar^
bürg, FRG). The apolipoprotein E antiserum was diluted in the
phosphate buffer. A 10 fold dilution of the filtered (MinisartR P,
Sartorius, Göttingen, FRG, pore size 0.45 ) antiserum was
found to be optimal for routine analysis. Samples of serum and the
d > 1.006 kg/l fraction were diluted 100 fold with phosphate buf-
fer, containing 0.15 mol of NaCl, 40 g of polyethylene glycol 6000
(Serva, Heidelberg, FRG), and 0.15 ml Tween 20R (Serva, Hei-
delberg, FRG) per liter. Usually, VLDL were delipidated with an
equal volume of tetramethylurea and diluted 50 fold. The reaction
mixture contained 0.2 ml of diluted antiserum and 0.1 ml of the
diluted sample and was allowed to stand for 2 h at 23 °C. The
apolipoprotein E concentration of serum and lipoprotein fractions
was obtained from serial dilutions of isolated apolipoprotein E in
the sample buffer. The light scattering was plotted against the
apolipoprotein E concentration to generate the Standard curve
from which the serum and lipoprotein apolipoprotein E concen-
trations could be determined.
Apolipoprotein E quantitation by electroimmunoassay
Rocket immunoelectrophoresis was done in 12.5 g/l agarose
plates using a 0.02 mol/1 barbital buffer, pH 8.6, after adding
30 g/l of apolipoprotein E antiserum at 52 °C (22). 5 mm diame-
ter holes for 15 samples were punched at the cathodal end. Serum
samples were diluted 10 fold in barbital buffer. The apolipopro-
tein E concentration of serum and lipoprotein fractions was ob-
tained from a Standard curve of isolated apolipoprotein E
(0.020 - 0.040 g/l, 5 points, r = 0.94). For staining Coomassie
Blue R 250 (Serva, Heidelberg, FRG) was used. The height of the
rockets was measured with a ruler to the nearest 0.5 mm. The
within-run coefficient of correlation (CV) was 1.6% (20 determi-
nations). The day-to-day CV was 3.9% (15 days).
Results
Analytical variables
With detergent solution present the background
light scattering was generally so low (< 3%) that it
could be neglected up to a serum triglyceride con^
centration of 20.0 g/l, VLDL were delipidated with
tetramethylurea priof to the assay without changing
the immunoreactivity. The kinetics of the immune
complex formation for isolated apolipoprotein E and
apolipoprotein E present in serum and delipidated
VLDL were identical, indicating similar exposure öf
the antigenic sites of apolipoprotein E (fig. 1). Max-
imal light scattering was reached after 2 h incubation
at 23 °C. In a series of 20 aliquots of a qtiality control
serum (mean apolipoprotein E concentration
0.091 g/1) the within-run CV was 2.3%. The day-to-
day CV was 4.7% äs measured during 15 consecu-^
tive days. The log-log Standard curve of apolipopro-
teiii E was linear within the ränge of 0.020 to
0.400 g/l apolipoprotein E (fig. 2). The lowest con-
centration that could be detected was 0.005 g/l apo-
lipoprotein E.
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Fig. 1. Light scattering of the immunoreaction between apolipo-
protein E antiserum and serum (1), VLDL (2), or isolated
apolipoprotein E (3) äs a function of the tirne.
100 fold diluted serum and apolipoprotein E (0.085 g/l)
and 50 fold diluted VLDL were mixed with a dilution of
antibody solution äs described. Light scattering was mea-
sured during 3 h at 23 °C.
The comparison of results obtained by immunone-
phelometry and electroimmunoässay (10 normal se-
ra and 10 hyperlipoproteinaemic sera) resulted in a
good correlation between the 2 assays (y = 1:03 —
0.06, r = 0.93). v *
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Fig. 2. Double-logarithmic plot of light scattering from isolated
apolipoprotein E. Light scattering was measured aftcr 2 h
for apolipoprotein E (0.020-0.400 g/l) äs described.
Tab. I . Fasting serum apolipoprotcin E concentration in normal
and hyperlipoproteinaemic subjects.
Subjects
Normal
(n = 20)
Type
(n =
Type
(n =
Type
(n =
Ha
10)
II b
10)
III
3)
Type IV
(n = 10)
Serum
cholesterol
(g/D
x ± S D
ränge
2
1
3
2
3
2
.06
.38
.96
.78
.12
.74
5.69
5.47
2
2
.83
.07
±0.34
-2.61
± 1.48
-5.30
±0.59
-4.69
±0.30
-5.90
± 1.02
-4.93
Serum
triglycerides
(g/l)
x ± S D
ränge
0.75 ±
0.45-
1.19±
0.76-
2
1
.09 +
.64-
6.98 ±
6.90-
5
2
.82 ±
.31 -
0
1
.19
.13
0.32
1.49
0
3
0
7
3
15
.67
.56
.21
.06
.82
.91
Serum
apolipoprotein E
(g/l)
x ± S D
ränge
0.103
0.084
0
0
0
0
0
0
0
0
.113
.096
.109
.098
.426
.363
.115
.097
± 0.008
-0.118
±0.011
-0.128
± 0.008
-0.123
± 0.022
- 0.549
±0.011
-0.132
Apolipoprotein E concentration in serum
The serum apolipoprotein E levels in normal and hy-
perlipoproteinaemic subjects are summarized in ta-
ble l. The mean apolipoprotein E concentration of
the normal subjects was 0.103 ± 0.008 g/l. The
mean in males (n = 8) did not differ from that in fe-
males (n = 12). Furthermore, the serum apolipopro-
tein E concentrations in Type II a, II b, and IV hy-
perlipoproteinaemias were similar to the normal
values. As expected, the apolipoprotein E levels of
the 3 patients with Type III hyperlipoproteinaemia
were nearly 4 fold higher than the other ones.
Distribution of apolipoprotein E among lipoproteitis
The distribution of apolipoprotein E among VLDL
and the d > l .006 kg/l fraction after ultracentrifuga-
tion was investigated in normal and hyperlipoprotei-
naemic subjects (tab. 2). The portion of lipoprotein-
associated apolipoprotein E found in VLDL was
similar in normal and Type II subjects, while Type
IV patients had an elevated apolipoprotein E con-
tent in this density ränge. In Type III patients Sepa-
ration of the lipoproteins by ultracentrifugation gave
a still higher portion of VLDL apolipoprotein E in
the other groups.
Discussion
This report describes the development and first ap-
plication of a sensitive and specific assay for human
apolipoprotein E in serum and lipoproteins using
laser immunonephelometry. This technique, first
applied to the assay of apolipoprotein B (23, 24), is
more suitable for the handling of small äs well äs of
large numbers of samples than other immunochemi-
Tab. 2. Distribution of apolipoprotein E in VLDL (d < 1.006 kg/l) and in the d > 1.006 kg/l fraction.
Subjects
Normal
(n = 6)
Typell
(n = 5)
Type III
(n = 2)
Type IV
(n = 5)
Serum cholesterol
(ränge)
(g/l)
1.72-2.39
2.87 - 4.07
5.47 - 5.90
2.16-3.55
Serum triglycerides Serum apolipoprotein E Percent distribution of apolipoprotein E in
(ränge) (ränge) lipoproteins of the density ranges
(g/0
0.90- 1.88
1.04- 3.02
6.90- 7.06
4.39- 11.73
(g/l)
0.099-0.115
0.108-0.123
0.363 - 0.549
0.097-0.132
d< 1.006 kg/l
(ränge)
22.2 - 28.9
21.2-26.6
48.0 - 54.9
29.9 - 35.7
d> 1.006 kg/l
(ränge)
71.1 -77.8
73.4 - 78.8
45.1 -52.0
64.3-70.1
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cal assays. The precision of immunonephelometry
fulfils the criteria required for Standard procedures
in clinical chemistry. Standardization of the method
described is possible with isolated apolipoprotein E.
The serum apolipoprotein E levels measured by las-
er immunonephelometry and electroirnmunoassay
were highly correlated, and each procedure was ac-
ceptable on the basis of its precision.
In assessing the serum apolipoprotein E concentra-
tion of normal subjects, \ve found values similar to
that of Curry at al. (9) and Mackie et al. (13) using
an electroimmunoassay and radioimmunoassay
procedure respectively. Other authors published
higher (10) or lower (8,11) absolute values of serum
apolipoprotein E. The discrepancies may be related
to differences in apolipoprotein E preparations, an-
tisera, and sample treatment procedures. In our
study only Type III patients had distinctly elevated
serum apolipoprptein E levels, while other found
elevated serum apolipoprotein E concentrations in
servere hypertriglyceridaemia (9, 11) or hypercho-
lesterolaemia(13) too. In some cases an incomplete
catabolism of triglyceride-rich lipoproteins or unusu-
al synthetic products may account for an increase of
the serum apolipoprotein E concentration.
Our observation on the lipopfotein distfibution of
apolipoprotein E in normals is consistent with the
data of the literature (8—13). In ia'greement with
Blum et al. (11), who used a radioimmunoassay
technique, a shift to more VLDL-associated apoji-
poprotein E cöuld be detected in Type IV hyperfipo*
proteinaemia. In Type III hyperiipoprotemaemia
about 50% of apolipoprotein E is in the VLDL-den-
sity ränge. These findings must be evahiated in the
light of the fact that the ultracentrifugation proce-
dure results in the appearance of considerable
amounts of apolipopfoteiii E in the lipoprotek-free
fraction of serum (11, 13).
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